JIP
SLXP

Jaffetilchin Investment Partners’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Jaffetilchin Investment Partners’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-7,761
Closed -$957K – 256
2014
Q2 		$957K Buy
7,761
+4,164
+116% +$460K 0.34% 40
2014
Q1 		$373K Buy
+3,597
New +$368K 0.15% 110

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jaffetilchin Investment Partners's SLXP Position: Q3 2014 in Review

Jaffetilchin Investment Partners sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 7,761 shares — an estimated $957K sold.

Jaffetilchin Investment Partners first reported a position in SLXP in Q1 2014 and held it in 2 quarters. The position peaked at $957K in Q2 2014. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • Jaffetilchin Investment Partners reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 7,761 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $957K.
  • Jaffetilchin Investment Partners first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q1 2014 and held it in 2 quarters.
  • Jaffetilchin Investment Partners's SALIX PHARMACEUTICALS LTD DEL position peaked at $957K in Q2 2014.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on Jaffetilchin Investment Partners's 13F filing for Q3 2014, filed 7 Nov 2014.